"This Medical Reviewer is concluding that there is an increased risk of cardiovascular thrombotic events, particularly myocardial infarction, in the rofecoxib group compared with the naproxen group." [FDA]
See page 34 of Dr. Shari L. Targum's memo (linked above).
